|
US6891082B2
(en)
*
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
WO1999010364A1
(en)
|
1997-08-29 |
1999-03-04 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
US5942420A
(en)
|
1997-11-17 |
1999-08-24 |
Millennium Biotherapeutics, Inc. |
Molecules of the follistatin-related protein family and uses therefor
|
|
US6797271B2
(en)
*
|
1999-03-25 |
2004-09-28 |
Genesis Research & Development Corporation Limited |
Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
|
|
US7083791B2
(en)
|
1999-03-25 |
2006-08-01 |
Genesis Research & Development Corporation Limited |
Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
|
|
WO2002038175A1
(en)
*
|
2000-11-07 |
2002-05-16 |
Immunovaccine Technologies Inc. |
Vaccines with enhanced immune response and methods for their preparation
|
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
|
WO2002080952A2
(en)
*
|
2001-04-09 |
2002-10-17 |
Lorantis Limited |
Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
|
|
AUPR638101A0
(en)
*
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
|
GB2385052A
(en)
*
|
2002-02-05 |
2003-08-13 |
Leuven K U Res & Dev |
Treatment of spondyloarthropathies
|
|
EP1572934A4
(en)
*
|
2002-02-21 |
2007-12-19 |
Wyeth Corp |
FOLLISTATIN DOMAIN CONTAINING PROTEINS
|
|
AU2003217612A1
(en)
*
|
2002-02-21 |
2003-09-09 |
Wyeth |
GASP1: a follistatin domain containing protein
|
|
AU2003211375A1
(en)
*
|
2002-02-27 |
2003-09-09 |
Science Park Corporation |
Computer file system driver control method, program thereof, and program recording medium
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
CA2510715A1
(en)
|
2002-12-20 |
2004-07-08 |
Enkam Pharmaceuticals A/S |
Method of modulation of interaction between receptor and ligand
|
|
AU2003901267A0
(en)
*
|
2003-03-19 |
2003-04-03 |
Monash University |
Assessment method
|
|
KR20060026860A
(ko)
|
2003-06-02 |
2006-03-24 |
와이어쓰 |
신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
|
|
EP1677816B1
(en)
*
|
2003-10-06 |
2014-03-12 |
Paranta Biosciences Limited |
Follistatin for use in down-regulation an inflammatory response
|
|
EP3059245B1
(en)
*
|
2004-07-23 |
2018-11-07 |
Acceleron Pharma Inc. |
Actrii receptor antagonistic antibodies
|
|
US20060257935A1
(en)
*
|
2005-04-26 |
2006-11-16 |
Ajinomoto Co., Inc. |
Hematopoietic factor production promoter
|
|
SI1915397T1
(sl)
|
2005-08-19 |
2015-05-29 |
Wyeth Llc |
Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
|
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
|
MX2008006626A
(es)
|
2005-11-23 |
2008-09-24 |
Acceleron Pharma Inc |
Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
US20070275036A1
(en)
|
2006-05-18 |
2007-11-29 |
Celldyne Biopharma, Llc |
Avian follistatin product
|
|
US10835576B2
(en)
|
2006-05-18 |
2020-11-17 |
Myos Rens Technology Inc. |
Method of obtaining effective amounts of avian follistatin
|
|
EP2097095B1
(en)
|
2006-11-29 |
2016-01-27 |
Nationwide Children's Hospital |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
WO2008094708A2
(en)
*
|
2007-02-01 |
2008-08-07 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
|
TWI782836B
(zh)
*
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
TWI606062B
(zh)
|
2007-02-09 |
2017-11-21 |
艾瑟勒朗法瑪公司 |
包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
|
|
US20100279409A1
(en)
*
|
2007-09-13 |
2010-11-04 |
Neil Robson |
Method for modifying celluar immune resonse by modulating activin activity
|
|
WO2009038745A1
(en)
*
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
JP5731198B2
(ja)
*
|
2007-09-27 |
2015-06-10 |
イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. |
インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
|
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
AU2009253780B2
(en)
*
|
2008-06-05 |
2014-08-14 |
Immunovaccine Technologies Inc. |
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
|
CA2729096C
(en)
|
2008-06-26 |
2020-04-28 |
Acceleron Pharma Inc. |
Methods for dosing an actriib antagonist and monitoring of treated patients
|
|
KR20190049912A
(ko)
|
2008-06-26 |
2019-05-09 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
HRP20191109T1
(hr)
|
2008-08-14 |
2019-09-20 |
Acceleron Pharma Inc. |
Gdf klopke za uporabu u liječenju anemije
|
|
WO2010083034A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
AU2010258931B2
(en)
|
2009-06-08 |
2015-04-23 |
Acceleron Pharma Inc. |
Methods for increasing thermogenic adipocytes
|
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
|
ES2869580T3
(es)
|
2009-09-09 |
2021-10-25 |
Acceleron Pharma Inc |
Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
|
|
EP3260130B1
(en)
*
|
2009-11-03 |
2021-03-10 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
CA2781152A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
DK2402288T3
(en)
|
2010-07-02 |
2017-02-06 |
Alfa Laval Corp Ab |
GAS SCRUBBER FLUID CLEANING EQUIPMENT
|
|
JP2014502260A
(ja)
|
2010-11-08 |
2014-01-30 |
アクセルロン ファーマ, インコーポレイテッド |
Actriia結合剤およびその使用
|
|
CN103492016A
(zh)
|
2010-11-23 |
2014-01-01 |
普莱萨格生命科学公司 |
用于实体递送的治疗方法和组合物
|
|
CN113876945A
(zh)
|
2011-10-06 |
2022-01-04 |
免疫疫苗技术有限公司 |
包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
|
|
GR1007832B
(el)
*
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
CA2867202A1
(en)
*
|
2012-05-17 |
2013-11-21 |
Paranta Biosciences Limited |
A method of treatment and agents useful for same
|
|
KR101704893B1
(ko)
|
2012-06-15 |
2017-02-08 |
화이자 인코포레이티드 |
Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
|
|
IL290653B2
(en)
|
2012-10-24 |
2025-05-01 |
Celgene Corp |
Biomarker for use in the treatment of anemia
|
|
ES2884095T3
(es)
|
2012-11-02 |
2021-12-10 |
Celgene Corp |
Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
|
|
US20150361163A1
(en)
|
2014-04-18 |
2015-12-17 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
MA40008A
(fr)
|
2014-06-13 |
2021-05-05 |
Acceleron Pharma Inc |
Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
|
|
CN104161959A
(zh)
*
|
2014-08-25 |
2014-11-26 |
山西藏象康寿科技有限公司 |
一种预防或治疗女性乳房不适症状的药食同源植物提取物制剂及制备方法
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
AU2015358469B2
(en)
|
2014-12-03 |
2021-05-27 |
Acceleron Pharma Inc. |
Activin-ActRII antagonists and uses for treating anemia
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
JP2016131541A
(ja)
*
|
2015-01-20 |
2016-07-25 |
学校法人藤田学園 |
トランスジェニック非ヒト哺乳動物及びその用途
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
EP3828199B1
(en)
|
2015-04-06 |
2025-10-15 |
Acceleron Pharma Inc. |
Alk7: actriib heteromultimers and uses thereof
|
|
WO2017079591A2
(en)
|
2015-11-04 |
2017-05-11 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
AU2016359695A1
(en)
|
2015-11-23 |
2018-06-14 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
|
US20170306027A1
(en)
|
2016-04-06 |
2017-10-26 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
HUE054228T2
(hu)
|
2016-07-15 |
2021-08-30 |
Acceleron Pharma Inc |
Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
|
|
PL3490582T3
(pl)
|
2016-07-27 |
2024-09-23 |
Acceleron Pharma Inc. |
Kompozycje do zastosowania w leczeniu mielofibrozy
|
|
EP3522934A4
(en)
|
2016-10-05 |
2020-04-15 |
Acceleron Pharma Inc. |
COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES
|
|
JP2023507794A
(ja)
|
2019-12-20 |
2023-02-27 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋肉疾患の筋肉を標的とするための最適化された遺伝子療法
|
|
AU2024256934A1
(en)
|
2023-04-18 |
2025-11-06 |
Research Institute At Nationwide Children's Hospital, Inc. |
Gene therapy for treating limb girdle muscular dystrophy r9 and congenital muscular dystrophy 1c
|
|
WO2025188993A2
(en)
|
2024-03-07 |
2025-09-12 |
Research Institute At Nationwide Children's Hospital |
Gene therapy for treating gne-related disorders
|